Advanced Enzyme Technologies Limited shareholders approved the reappointment of Mukund Madhusudan Kabra as Whole-time Director and the appointment of Pradip Bhailal Shah as Independent Director at its 37th Annual General Meeting (AGM) held on July 31, 2026. The meeting also saw the reappointment of MSKA & Associates LLP as statutory auditors for a five-year term, alongside the declaration of a final dividend of ₹1.35 per equity share for FY26. These governance decisions ensure continuity in leadership and financial oversight for the enzyme manufacturer.

The detailed outcomes were disclosed in a filing with BSE Limited and National Stock Exchange of India Ltd on August 1, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The resolutions were part of the special and ordinary business items addressed during the virtual AGM, which was scrutinized by Shiv Hari Jalan & Co.

Key Appointments and Tenures

The Board sought shareholder approval for critical leadership roles to align with regulatory requirements and corporate governance standards. The following table details the specific tenures approved for the key appointees:

Ms. Rasika Rathi was also re-appointed as a Director after retiring by rotation. The approval of these appointments ensures compliance with the Companies Act, 2013, regarding board composition and auditor rotation norms.

Auditor Reappointment Details

MSKA & Associates LLP, Chartered Accountants (FRN: 105047W/W101187), was reappointed for a second term. This term covers the period from the conclusion of the current AGM until the conclusion of the 42nd AGM, scheduled for the financial year ended March 31, 2031. The reappointment follows the mandatory process outlined in Schedule III of the SEBI LODR Regulations.

Voting Results and Shareholder Sentiment

While promoter support was near-universal, public institutional investors expressed dissent on certain governance matters. The appointment of Mr. Pradip Bhailal Shah faced 3.09% opposition in valid votes, with public institutions voting against it at a rate of 11.77%. Similarly, the remuneration approval for Ms. Manasi Kabra, an immediate relative of the Whole-time Director, saw 16.11% opposition from public institutions, though it passed with 95.61% overall support. Material related-party transactions with JC Biotech Private Limited were approved with promoter votes excluded as per Regulation 23(4) of the SEBI LODR Regulations.

Advanced Enzyme Technologies Limited has scheduled a meeting of its Board of Directors for Saturday, August 08, 2026. The primary agenda includes the consideration and approval of the company's un-audited financial results for the first quarter ended June 30, 2026, as well as a proposal for the buyback of equity shares.

The decision to pursue a share buyback is subject to the provisions of the Companies Act, 2013, rules made thereunder, and the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended. This corporate action signals management's intent to return capital to shareholders or optimize capital structure, pending final approval during the scheduled session.

Key Agenda Items

The Board will address the following critical matters:

Trading Window Closure

In compliance with regulatory norms regarding insider trading prevention, the trading window for dealing in the securities of Advanced Enzyme Technologies Limited remains closed. The closure, initially intimated in a letter dated June 25, 2026, will continue until August 10, 2026. This restriction applies to all designated persons of the company who are in possession of unpublished price-sensitive information.

Regulatory Disclosures

The intimation regarding the board meeting and trading window closure was issued on August 01, 2026, and signed by Sanjay Basantani, Company Secretary and Head – Legal. The notice has been uploaded to the company's website at www.advancedenzymes.com and is accessible via the stock exchange websites at www.bseindia.com and www.nseindia.com . The company is listed on BSE Limited under Scrip Code 540025 and on the National Stock Exchange of India Ltd. under the trading symbol ADVENZYMES.